CSF1R and neoplasm: However, therapeutic approaches face contradictions; while TAM depletion (e.g., CSF-1R inhibitors) reduces tumor burden, it may impair anti-tumor immunity, whereas reprogramming strategies risk incomplete phenotype conversion or context-dependent efficacy [347,348].